secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040136
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q2 net loss $18.3M; cash $162M; Phase 3 trial on track for H2 2023 dosing
--------------------------------------------------------------------------------

- Net loss $18.3M vs $13.5M in Q2 2022; R&D expenses rose to $15.1M on Phase 3 start-up.
- Cash and marketable securities $162.0M; expected to fund operations into H2 2025.
- Phase 3 trial of bel-sar for choroidal melanoma enrolling; first patient dosing expected H2 2023; commercial material released.
- Key leadership appointments: Bruce Brown (Urologic Oncology), Anthony Daniels (Ocular Oncology), Richard Mountfield (SVP Regulatory).
- Phase 1 NMIBC trial ongoing; data expected 2024; Plan Phase 2 in choroidal metastasis in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/0000950170-23-040136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/aura-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer